Recent FTC Warning Letters Target CBD Medical Claims

September 10, 2019, the U.S. Federal Trade Commission (“FTC”) issued a news release announcing the recent distribution of warning letters to three companies advertising cannabidiol (“CBD”) products as a medical treatment option for a range of various illnesses. Cautioning that such unsubstantiated … Read more about Recent FTC Warning Letters Target CBD Medical Claims

Proposed California CBD Bill Suspended

Contrary to the bill’s projected outcome from earlier in the summer, California lawmakers will not make a decision on Assembly Bill-228 (“AB 228”) this year as the bill has stalled in the state legislature despite broad bipartisan interest and consumer support. Previously expected to be signed into … Read more about Proposed California CBD Bill Suspended

FDA Plans Release of CBD Regulations by Fall 2019

Cannabidiol (“CBD”) products have gained popularity across the country, but clear regulation from the Food and Drug Administration (“FDA”) is still forthcoming. This July, FDA announced an intent to fast- track the process to create these much-needed regulations. Currently, nearly 90% of CBD … Read more about FDA Plans Release of CBD Regulations by Fall 2019

Revisiting the War on Drugs & Its Impact

July 14 marked the 50th anniversary of President Richard Nixon’s message to Congress asking for the establishment of a federal plan to tackle substance abuse, citing a dramatic increase in juvenile arrests for drug offenses. Nixon’s letter was the start of a new era of American drug policy as, the … Read more about Revisiting the War on Drugs & Its Impact

Largest U.S. CBD Company Hit with Warning Letter from FDA

On July 22, 2019, the United States Food and Drug Administration (“FDA”) sent a Warning Letter (the “Letter”) to Curaleaf, Inc. notifying the company that FDA considers several products Curaleaf sells on its website, specifically its  “CBD Lotion,” “CBD Pain-Relief Patch,” five versions of its “CBD … Read more about Largest U.S. CBD Company Hit with Warning Letter from FDA

New Data Projects Decrease in CBD Prices

Cannabidiol (“CBD”) products have garnered unprecedented levels of market interest following the Agriculture Improvement Act of 2018 (“2018 Farm Bill”). Indeed, even though the Food and Drug Administration (“FDA”) still considers ingestible CBD consumer products to be prohibited – the drug Epidiolex … Read more about New Data Projects Decrease in CBD Prices

Firm Attends FDA Hearing on Cannabis and Derived Products

  Last Friday, May 31, the U.S. Food and Drug Administration (“FDA”) held their first public hearing regarding cannabis and cannabis-derived products.  Influenced by the recent market boom of hemp and cannabidiol (“CBD”) products, the FDA’s hearing presented an opportunity for industry … Read more about Firm Attends FDA Hearing on Cannabis and Derived Products

USDA Defends Interstate Transportation of Hemp

Earlier this week, the United States Department of Agriculture (“USDA”) issued a bulletin regarding the agency’s current view on hemp’s legality after the Agriculture Improvement Act of 2018 (“2018 Farm Bill”). In a memorandum to U.S. Secretary of Agriculture Sonny Perdue, USDA attorney Stephen … Read more about USDA Defends Interstate Transportation of Hemp